Yahoo
NasdaqGS - Delayed Quote USD

Xeris Biopharma Holdings, Inc. (XERS)

8.53 -0.06 (-0.70%)
At close: September 4 at 4:00:00 PM EDT
8.54 +0.01 (+0.12%)
After hours: September 4 at 7:30:02 PM EDT
Trade XERS on Coinbase
Chart Range Bar
Loading chart for XERS
  • Previous Close 8.59
  • Open 8.50
  • Bid 6.05 x 200
  • Ask 10.75 x 200
  • Day's Range 8.39 - 8.59
  • 52 Week Range 5.25 - 10.08
  • Volume 1,030,324
  • Avg. Volume 1,869,537
  • Market Cap (intraday) 1.555B
  • Beta (5Y Monthly) 0.85
  • PE Ratio (TTM) --
  • EPS (TTM) -0.10
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 11.71

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

www.xerispharma.com

435

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

XERS
8.66%
S&P 500 (^GSPC)
12.75%

1-Year Return

XERS
8.11%
S&P 500 (^GSPC)
18.71%

3-Year Return

XERS
259.92%
S&P 500 (^GSPC)
70.93%

5-Year Return

XERS
213.60%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 92.1M
Earnings -31.1M
Profit Margin -33.77%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-20M
0
20M
40M
60M
80M
-30.0%
-20.0%
-10.0%
0.0%
10.0%

Analyst Insights

View More

Analyst Price Targets

8.00
11.71 Average
8.53 Current
18.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/20/2026
Analyst Barclays
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 9 -> 12

Statistics

View More

Valuation Measures

Annual
As of 9/3/2026
  • Market Cap

    1.57B

  • Enterprise Value

    1.73B

  • Trailing P/E

    115.93

  • Forward P/E

    36.50

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.63

  • Price/Book (mrq)

    107.68

  • Enterprise Value/Revenue

    5.17

  • Enterprise Value/EBITDA

    72.57

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -5.12%

  • Return on Assets (ttm)

    6.13%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    335.41M

  • Net Income Avi to Common (ttm)

    -17.16M

  • Diluted EPS (ttm)

    -0.10

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    121.75M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    52.45M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

8.53 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: